David Hoang
Stock Analyst at Deutsche Bank
(3.65)
# 753
Out of 5,150 analysts
47
Total ratings
48.65%
Success rate
9.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Hoang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APGE Apogee Therapeutics | Initiates: Buy | $103 | $72.31 | +42.44% | 1 | Dec 10, 2025 | |
| ALKS Alkermes | Maintains: Buy | $55 → $45 | $29.28 | +53.69% | 3 | Nov 13, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $65 → $280 | $325.11 | -13.88% | 2 | Oct 17, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Buy | $43 | $41.00 | +4.88% | 1 | Sep 26, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $54 → $36 | $28.54 | +26.14% | 4 | Sep 25, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Sell | $6 → $12 | $16.09 | -25.42% | 10 | Aug 15, 2025 | |
| ACAD ACADIA Pharmaceuticals | Upgrades: Buy | $20 → $35 | $23.39 | +49.64% | 5 | May 21, 2025 | |
| XENE Xenon Pharmaceuticals | Initiates: Buy | $67 | $43.05 | +55.63% | 3 | Feb 11, 2025 | |
| DNLI Denali Therapeutics | Initiates: Buy | $31 | $20.37 | +52.18% | 3 | Feb 11, 2025 | |
| BHVN Biohaven | Initiates: Buy | $65 | $10.61 | +512.63% | 1 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $176 | $164.08 | +7.26% | 4 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $150 → $158 | $133.44 | +18.41% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $3.31 | +111.48% | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $6.14 | +160.59% | 1 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $4.13 | +287.41% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $220 | $327.30 | -32.78% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $65.10 | +22.89% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $3 | $0.58 | +417.24% | 1 | Dec 7, 2022 |
Apogee Therapeutics
Dec 10, 2025
Initiates: Buy
Price Target: $103
Current: $72.31
Upside: +42.44%
Alkermes
Nov 13, 2025
Maintains: Buy
Price Target: $55 → $45
Current: $29.28
Upside: +53.69%
Praxis Precision Medicines
Oct 17, 2025
Maintains: Buy
Price Target: $65 → $280
Current: $325.11
Upside: -13.88%
Spyre Therapeutics
Sep 26, 2025
Initiates: Buy
Price Target: $43
Current: $41.00
Upside: +4.88%
Harmony Biosciences Holdings
Sep 25, 2025
Maintains: Buy
Price Target: $54 → $36
Current: $28.54
Upside: +26.14%
Sarepta Therapeutics
Aug 15, 2025
Maintains: Sell
Price Target: $6 → $12
Current: $16.09
Upside: -25.42%
ACADIA Pharmaceuticals
May 21, 2025
Upgrades: Buy
Price Target: $20 → $35
Current: $23.39
Upside: +49.64%
Xenon Pharmaceuticals
Feb 11, 2025
Initiates: Buy
Price Target: $67
Current: $43.05
Upside: +55.63%
Denali Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $31
Current: $20.37
Upside: +52.18%
Biohaven
Feb 11, 2025
Initiates: Buy
Price Target: $65
Current: $10.61
Upside: +512.63%
Feb 11, 2025
Initiates: Buy
Price Target: $176
Current: $164.08
Upside: +7.26%
Aug 2, 2024
Maintains: Neutral
Price Target: $150 → $158
Current: $133.44
Upside: +18.41%
Jul 25, 2024
Initiates: Buy
Price Target: $7
Current: $3.31
Upside: +111.48%
Mar 15, 2024
Initiates: Buy
Price Target: $16
Current: $6.14
Upside: +160.59%
Mar 7, 2024
Initiates: Buy
Price Target: $16
Current: $4.13
Upside: +287.41%
Apr 26, 2023
Initiates: Neutral
Price Target: $220
Current: $327.30
Upside: -32.78%
Apr 26, 2023
Initiates: Outperform
Price Target: $80
Current: $65.10
Upside: +22.89%
Dec 7, 2022
Downgrades: Neutral
Price Target: $3
Current: $0.58
Upside: +417.24%